Interview with Olivier Daubry, General Manager, Celgene France
In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head…
Address: 16/18, Rue du Quatre Septembre
75002 Paris
,France
Tel: +33 1 53 42 43 00
Celgene is a multinational biopharmaceutical company committed to improving the lives of patients worldwide.
Celgene seeks to deliver truly innovative and life-changing drugs for our patients. It’s mission as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.
Thanks to the establishment of its structure in France, a 100% subsidiary of Celgene Corporation, Celgene France ensures its presence on the French health market. Celgene France, besides the marketing of drugs, will establish many clinical trials of new molecules derived from the R&D of Celgene. These, of course, will be conducted in cooperation with the most recognized French medical institutions.
There are numerous clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocyte leukemia (CLL), non-Hodgkin’s lymphoma (NHL), glioblastoma, and ovarian, pancreatic and prostate cancer.
Global Products
ISTODAX® (romidepsin) for injection
REVLIMID® (lenalidomide)
THALOMID® (thalidomide)
VIDAZA® (azacitidine for injection)
Services
LifebankUSA (placental and cord blood banking)
In only four years Celgene has introduced a number of important products in the French market and is now seen as a preeminent biopharmaceutical company in hematology. As the head…
The latest news from French pharma, including why President Emmanuel Macron’s initiative to bring medical production back to Europe has hit a wall, Sanofi’s slow progress towards finally bringing its…
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed the headlines over the past year for their work on COVID-19 vaccines, smaller and lesser-known companies are also playing…
The latest from French pharma where Sanofi has inked a deal to produce 125 million doses of Pfizer’s COVID-19 vaccine as it faces delays with its in-house product and the…
A roundup of the latest stories from French pharma, including the progress of Sanofi’s COVID-19 vaccine, how Ipsen has managed to achieve sales growth in 2020 despite the pandemic, diagnostics…
A roundup of some of the latest from French pharma, including Sanofi’s bumper Prinicipia deal, how Unither’s new Chinese acquisition catapults it into the world’s top 5 CDMOs, Ipsen’s resilient…
Sanofi has agreed a deal to buy out its partner, US biotech company Principia Biopharma for USD 3.7 billion in cash, giving the French giant full ownership of Principia’s pipeline…
With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe as the new head of its vaccines business unit, Sanofi Pasteur, on…
French firm LFB is targeting the lucrative US market with its hemophilia products and recently received two FDA approvals. Although launching new products in the midst of a global pandemic…
French pharma giant Sanofi is pivoting its focus to invest more heavily in vaccines with a plan to invest USD 679 million in vaccine manufacturing operations in the next two…
David Loew, formerly executive vice president of Sanofi Pasteur, Sanofi’s vaccines division, was appointed CEO of fellow French firm Ipsen on the 28th May 2020, effective 1st July. Loew,…
Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments. …
In a recent interview with Financial Times, Sanofi CEO Paul Hudson set out to clarify some recent comments that the US would get priority access to a COVID-19 vaccine. He…
See our Cookie Privacy Policy Here
